Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Elite Pharmaceuticals (ELTP)
OTHER OTC:ELTP
Holding ELTP?
Track your performance easily
ELTP Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.12 - $0.75
Previous Close$0.55
Volume755.86K
Average Volume (3M)2.86M
Market Cap
$608.92M
Enterprise Value$610.76M
Total Cash (Recent Filing)$9.55M
Total Debt (Recent Filing)$11.40M
Price to Earnings (P/E)―
Beta-0.32
Next Earnings
Feb 17, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,068,273,108
10 Day Avg. Volume1,625,685
30 Day Avg. Volume2,856,628
Standard Deviation0.21
R-Squared0.00360
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)13.74
Price to Sales (P/S)8.56
Price to Cash Flow (P/CF)104.50
P/FCF Ratio108.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.58
Enterprise Value/Gross Profit23.17
Enterprise Value/Ebitda-137.94
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Elite Pharmaceuticals News
PremiumCompany Announcements
Elite Pharmaceuticals Launches Generic Version of Norco
PremiumCompany Announcements
Elite Pharmaceuticals Gains FDA Approval for Generic Vyvanse
PremiumCompany Announcements
Elite Pharmaceuticals Reports Robust Q2 Financial GrowthPremiumCompany Announcements
Elite Pharmaceuticals Reports Strong Q2 2025 Financial Results
PremiumCompany Announcements
Elite Pharmaceuticals’ Generic Adderall® Approved in Israel
PremiumCompany Announcements
Elite Pharmaceuticals Launches Generic Pain Medication
PremiumCompany Announcements
Elite Pharmaceuticals Unveils Generic Methotrexate Tablets
PremiumCompany Announcements
Elite Pharmaceuticals: Navigating Stock Market ComplexitiesOwnership Overview
20.74% Insiders
0.01% Other Institutional Investors
79.25% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ELTP FAQ
What was Elite Pharmaceuticals’s price range in the past 12 months?
Elite Pharmaceuticals lowest stock price was $0.12 and its highest was $0.75 in the past 12 months.
What is Elite Pharmaceuticals’s market cap?
Currently, no data Available
When is Elite Pharmaceuticals’s upcoming earnings report date?
Elite Pharmaceuticals’s upcoming earnings report date is Feb 17, 2025 which is in 57 days.
How were Elite Pharmaceuticals’s earnings last quarter?
Elite Pharmaceuticals released its earnings results on Nov 14, 2024. The company reported -$0.01 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.01.
Is Elite Pharmaceuticals overvalued?
According to Wall Street analysts Elite Pharmaceuticals’s price is currently Overvalued.
Does Elite Pharmaceuticals pay dividends?
Elite Pharmaceuticals does not currently pay dividends.
What is Elite Pharmaceuticals’s EPS estimate?
Elite Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Elite Pharmaceuticals have?
Elite Pharmaceuticals has 1,068,273,100 shares outstanding.
What happened to Elite Pharmaceuticals’s price movement after its last earnings report?
Elite Pharmaceuticals reported an EPS of -$0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.692%.
Which hedge fund is a major shareholder of Elite Pharmaceuticals?
Among the largest hedge funds holding Elite Pharmaceuticals’s share is Fisher Asset Management LLC. It holds Elite Pharmaceuticals’s shares valued at N/A.
---
Elite Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
ELTP Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 82.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $562.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.6%
Last 30 Days ▲ 8.3%
Last 30 Days ▲ 8.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
289.36%
12-Months-Change
Fundamentals
Return on Equity
-13.83%
Trailing 12-Months
Asset Growth
24.72%
Trailing 12-Months
Company Description
Elite Pharmaceuticals
Elite Pharmaceuticals, Inc. engages in the development and manufacture of pharmacological abuse-deterrent opioid products. It operates through the Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA) segments. The ANDA segment includes generic pharmaceuticals. The NDA segment comprises the branded pharmaceuticals. The company was founded on October 1, 1997 and is headquartered in Northvale, NJ.
---
ELTP Earnings Call
Q2 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call demonstrated strong revenue and profit growth, supported by a robust pipeline and strategic facility expansion, though some supply chain challenges and financial liabilities were noted.Read More>---
Technical Analysis
---